HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

Bibliographic Details
Main Authors:	Harel Dahari, Laetitia Canini, Frederik Graw, Susan L. Uprichard, EvaldoS A. Araujo, Guillaume Penaranda, Emilie Coquet, Aurélie Riso, Christophe Renou, Marc Bourlière, Scott J. Cotler, Philippe Halfon
Format:	Article
Language:	English
Published:	Elsevier 2016-05-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020311225

Similar Items

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
by: Laetitia Canini, et al.
Published: (2017-01-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
by: Y. O. SHULPEKOVA, et al.
Published: (2017-05-01)

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
by: Miguel Malespin, et al.
Published: (2017-01-01)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
by: Eric Lawitz, et al.
Published: (2020-06-01)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015-12-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
by: Jona T Stahmeyer, et al.
Published: (2017-01-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
by: Sachiko Omotani, et al.
Published: (2020-04-01)

Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)
by: Sergio Vicente-Sánchez, et al.
Published: (2017-03-01)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
by: Yang CHT, et al.
Published: (2018-07-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
by: Jesús Quintero, et al.
Published: (2019-03-01)

Análise de custo-efetividade do tratamento precoce da hepatite viral C crônica com simeprevir, daclatasvir e sofosbuvir sob a perspectiva do Sistema Único de Saúde
by: Jarek, Nayara Almeida de Assis
Published: (2018)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
by: M. Shabani, et al.
Published: (2021-07-01)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
by: Andrew Hill, et al.
Published: (2016-01-01)

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin
by: Saverio G. Parisi, et al.
Published: (2016-08-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
by: Peter Buggisch, et al.
Published: (2019-01-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
by: D Issa, et al.
Published: (2016-01-01)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
by: Gaetano JN
Published: (2014-03-01)

Treatment of Recurrent Hepatitis C Genotype-4 Post- Liver Transplantation with Sofosbuvir plus Simeprevir
by: Mustafa Ascha, et al.
Published: (2015-04-01)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
by: Vincent Alcazer, et al.
Published: (2018-12-01)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
by: Nadia Marascio, et al.
Published: (2019-05-01)

Ledipasvir/sofosbuvir induced nephrotic syndrome: A challenging case of Hepatitis C management
by: Zaver, Himesh, et al.
Published: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
by: Naylor PH, et al.
Published: (2017-03-01)

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
by: Shih-Jer Hsu, et al.
Published: (2020-03-01)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
by: Giovanni Covini, et al.
Published: (2018-10-01)

Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir
by: Efemena Michael Diejomaoh MD, et al.
Published: (2017-03-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
by: Anne Laurain, et al.
Published: (2019-04-01)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
by: Gregory D Huhn, et al.
Published: (2020-01-01)

Clinical effect and safety of sofosbuvir-ledipasvir regimen in treatment of patients with HCV genotype 6a chronic hepatitis C
by: LI Wei
Published: (2019-03-01)